|
|
Vaccine Detail
|
Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007086
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- LV28_RS26095 transcriptional regulator RegF
gene engineering:
- Type: Recombinant protein preparation
- Description: (Xing et al., 2018)
- Detailed Gene Information: Click Here.
- Preparation: The vaccine is composed of hu-rhEGF conjugated to the carrier protein, r-P64K, and emulsified with the adjuvant Montanide ISA 51 VG (Xing et al., 2018).
- Description: This is for Lung Cancer (NCT00516685). A peptide vaccine preparation, containing recombinant human epidermal growth factor (rEGF) linked to the Neisseria meningitidis-derived recombinant immunogenic carrier protein P64k (rP64k) and mixed with the immunoadjuvant Montanide ISA 51, with potential active immunotherapy activity. Recombinant human EGF-rP64K/Montanide ISA 51 vaccine may trigger a humoral immune response against vaccine rEGF and rP64K and, so, against endogenous EGF. Antibody-mediated inhibition of endogenous EGF binding to its receptor, epithelial growth factor receptor (EGFR), may result in the inhibition of tumor cell proliferation (NCIT_C70674).
|
| Host Response |
|
|
| References |
NCIT_C70674: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C70674]
NCT00516685: [https://clinicaltrials.gov/show/NCT00516685/]
Xing et al., 2018: Xing P, Wang H, Yang S, Han X, Sun Y, Shi Y. Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer. BMC immunology. 2018; 19(1); 14. [PubMed: 29661145].
|
|
